<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931265</url>
  </required_header>
  <id_info>
    <org_study_id>108009-F</org_study_id>
    <nct_id>NCT03931265</nct_id>
  </id_info>
  <brief_title>Ketohexokinase Isoforms in Endometrial Cancer.</brief_title>
  <official_title>Prognostic Evaluations of Ketohexokinase Isoforms in Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our preliminary analysis with clinical database suggested that, in patients with type I
      endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities
      than low ketohexokinase-expressing group. To understand the importance of ketohexokinase
      expression and isoform switch during the development of type I endometrial cancer, we propose
      a series of in vitro experiments and clinical examinations in this project.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>The role of ketohexokinase isoforms in the overall survival of endometrial cancer.</measure>
    <time_frame>5 years</time_frame>
    <description>Cox proportional hazard regression to evaluate the role of ketohexokinase isoforms in the overall survival of endometrial cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of ketohexokinase isoforms with the other prognostic risk factors</measure>
    <time_frame>5 years</time_frame>
    <description>Correlation of ketohexokinase isoforms with deep myometrial invasion, tumor grade, lymph node metastasis, FIGO stage, tumor size, progression-free survival, etc.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ketohexokinase</intervention_name>
    <description>Check the isoforms of ketohexokinase in the specimen of endometrial cancer</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with endometrial cancer who underwent staging surgeries in the Far Eastern Memorial
        Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;20 years

          -  Women with endometrial cancer who are about to be admitted to hospital for
             gynecological staging.

          -  Women who have undergone gynecological staging surgery for endometrial cancer in the
             past.

        Exclusion Criteria:

          -  Women with endometrial cancer who receive preoperative chemotherapy or radiation
             therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng-Mou Hsiao, MD</last_name>
    <phone>+886289667000</phone>
    <phone_ext>1818</phone_ext>
    <email>smhsiao2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao</city>
        <state>New Taipei</state>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Mou Hsiao, M.D.</last_name>
      <phone>+886-2-89667000</phone>
      <phone_ext>1818</phone_ext>
      <email>smhsiao2@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Sheng-Mou Hsiao</investigator_full_name>
    <investigator_title>Chief, Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

